Form 8-K Relay Therapeutics, Inc. For: Sep 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Goldman Sachs Reinstates Relay Therapeutics (RLAY) at Buy
September 9, 2024 4:47 PM EDTGoldman Sachs analyst Salveen Richter reinstates coverage on Relay Therapeutics (NASDAQ: RLAY) with a Buy rating and a price target of $20.00.
The analyst comments "Given positive Ph2 data of selective PI3K inhibitor RLY-2608 + fulvestrant in PI3K-mutated HR+/HER2- breast cancer and planned Ph3 initiation in 2025, we reinstate RLAY with a Buy rating and $20 price... More
TD Cowen Out Positive on Relay Therapeutics (RLAY), Shares Up ~53%, 'we are constructive on Ph3 success based on today's data'
September 9, 2024 3:20 PM EDTTD Cowen analyst Yaron Werber reiterated a Buy rating on Relay Therapeutics (NASDAQ: RLAY).
The analyst comments "Our Take: RLY-2608 Impresses With Unparalleled 9.2 Months mPFS, 33% ORR, And Minimal Hyperglycemia Moving into Ph3 Vs AZN Truqap This morning, Relay announced positive interim data for the RLY-2608 + fulvestrant doublet in HR+/HER2- locally advanced or metastatic breast cancer showing unmatched efficacy on PFS and ORR, and continued differentiation on safety vs both approved therapies (AZN's Truqap & NVS' Piqray). In our view, this data is highly encouraging and... More
Relay Therapeutics (RLAY) Shares Gain ~51%, PT Raised to $17 at Barclays
September 9, 2024 3:03 PM EDTBarclays analyst Peter Lawson raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $17.00 (from $14.00) while maintaining a Overweight rating.
The analyst comments "We increase our probability of success for RLY-2608 in advanced HR+/HER2- breast cancer and increase our penetration rate... More
